Blood products company Haemonetics (NYSE:HAE). will be reporting results this Thursday morning. Here’s what you need to know.
Haemonetics beat analysts’ revenue expectations by 1% last quarter, reporting revenues of $330.6 million, down 3.7% year on year. It was a satisfactory quarter for the company, with a solid beat of analysts’ organic revenue estimates but a slight miss of analysts’ full-year EPS guidance estimates.
Is Haemonetics a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Haemonetics’s revenue to decline 10.3% year on year to $301.6 million, a reversal from the 8% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.02 per share.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Haemonetics has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 2.2% on average.
Looking at Haemonetics’s peers in the medical devices & supplies - specialty segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Integer Holdings delivered year-on-year revenue growth of 11.4%, beating analysts’ expectations by 2.6%, and Bausch + Lomb reported revenues up 5.1%, topping estimates by 2.2%. Integer Holdings traded down 6.3% following the results while Bausch + Lomb was also down 7%.
Read our full analysis of Integer Holdings’s results here and Bausch + Lomb’s results here.
Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the medical devices & supplies - specialty stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.1% on average over the last month. Haemonetics is up 1.3% during the same time and is heading into earnings with an average analyst price target of $92.45 (compared to the current share price of $76.11).
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.